Webinar Combatting Antimicrobial Resistance: The Legacy of the IMI COMBACTE Projects
On May 31st, the Innovative Health Initiative will host an Impact Webinar spotlighting the significant outcomes of the COMBACTE projects in combating antimicrobial resistance. Key speakers from across the COMBACTE consortium will highlight crucial milestones and underscore the critical role this private-public partnership has played in achieving its ambitious goals. This webinar will not only showcase the groundbreaking results but also emphasize the initiative’s success in addressing one of the most pressing health challenges of our time.
More info & registration
Speakers at the webinar are the scientific lead and management board member of COMBACTE Prof. Marc Bonten (UMC Utrecht), management board members and academic partners Jesus Rodriguez Bano (COMBACTE-CARE; University Hospital Virgen Macarena) and Bruno Francois (COMBACTE-NET, CHU Limoges), management board member and EFPIA partner in COMBACTE-NET Hasan Jafri (Aridis Pharma), Project Management Officer and EFPIA partner Halley Rogers (Pfizer) and Sr. Scientific Officer of the COMBACTE projects Nathalie Seigneuret (IHI).
Unprecedented Knowledge Sharing
The COMBACTE projects were created to meet the challenges of clinical development of antibacterials in response to the worldwide growing problem of antibiotic resistance.
In collaboration with other consortia within the IMI New Drugs 4 Bad Bugs (ND4BB) program, the projects set out enable more rapid and efficient development and commercialisation of much-needed new antibacterial treatments and diagnostic tests.
COMBACTE is a part of the Innovative Medicines Initiative (IMI) program: an unprecedented partnership between industry, academia and biotech organisations to combat antibiotic resistance in Europe by tackling the scientific, regulatory, and business challenges that are hampering the development of new antibiotics.
Results
COMBACTE has issued many study results published in (high-impact) infectious diseases journals. The featured Publication Library offers access to over 160 (open access) scientific papers with compelling science from all four projects: COMBACTE-NET, COMBACTE-MAGNET, COMBACTE-CARE and COMBACTE-CDI.
Major Achievement
Recently COMBACTE announced the major milestone achieved in COMBACTE-CARE. The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union for EMBLAVEO® (aztreonam-avibactam), a fixed-dose combination of two active substances – aztreonam and avibactam – for adult patients with infections due to antibiotic-resistant bacteria.
ATM-AVI is a beta-lactam/beta lactamase inhibitor combination intended to treat serious Gram-negative bacterial infections in patients with limited or no treatment options. Two of the ATM-AVI clinical studies were conducted with the support of project COMBACTE-CARE – the phase II and phase III studies, REJUVENATE and REVISIT respectively.
The collaboration between academia, industry and the clinical trial sites has been crucial to the success of the COMBACTE-CARE studies, leading to robust patient recruitment and knowledge sharing, as well as demonstrating the value of having a high-quality clinical and laboratory network in Europe.
10 Years of Impact
In its 10 years of running COMBACTE has built a critical infrastructure to fight antimicrobial resistance, in the form of a clinical and laboratory network. This infrastructure, which now continues in Ecraid, will allow to further build on the achievements in COMBACTE, and continue to be play a pivotal role in the context of infectious diseases and pandemic preparedness. Read all about the COMBACTE projects, trials and testimonials in the COMBACTE Magazine.
Related updates
“We Take Bigger Steps Together”
COMBACTE's Last General Assembly
COMBACTE Launches Last Magazine
COMBACTE launched its last magazine at ECCMID 2023 in Copenhagen. The magazine focuses on project’s impact, and features articles and interviews with ...